Cookie Img

Tacrolimus Pellets

Tacrolimus Pellets
Tacrolimus Pellets
Product Code : 03
Product Specifications
CAS No :
104987-11-3
Drug Type :
Medicine Raw Materials
Physical Form :
Powder
Product Description

Tacrolimus Pellets

Avanscure Lifesciences Pvt. Ltd., global Manufacturer of Tacrolimus 0.4 , 0.5  offers for your requirements of RND / Development quantities or commercials, based on status of the product.

Preventing organ rejection in certain patients following liver, kidney, or heart transplant. It may be used along with other medicines.

IUPAC NAME :- (1R,9S,12S,13R,14S,17R,21S,23S,24R,25S,27R)-1,14-dihydroxy-12-[(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl]-23,25-dimethoxy-13,19,21,27-tetramethyl-17-(prop-2-en-1-yl)-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetrone

CAS NO. :- 104987-11-3

FORMULA :- C44H69NO12

SYNONYMS :- FK-506;prograf;fr900506;L 679934;Protopic;Advagraf;Fujimycin;TacroBell;TACROLIMUS;FK-506, 99+%

APPLICATION :- For use after allogenic organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It was first approved by the FDA in 1994 for use in liver transplantation, this has been extended to include kidney, heart, small bowel, pancreas, lung, trachea, skin, cornea, and limb transplants. It has also been used in a topical preparation in the treatment of severe atopic dermatitis.

DESCRIPTION :- Tacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient immune system and so the risk of organ rejection. It is also used in a topical preparation in the treatment of severe atopic dermatitis, severe refractory uveitis after bone marrow transplants, and the skin condition vitiligo. 

Molar mass 804.018 g/mol



Tacrolimus Pellets

Avanscure Lifesciences Pvt. Ltd., global Manufacturer of Tacrolimus 0.4 , 0.5  offers for your requirements of RND / Development quantities or commercials, based on status of the product.

Preventing organ rejection in certain patients following liver, kidney, or heart transplant. It may be used along with other medicines.

IUPAC NAME :- (1R,9S,12S,13R,14S,17R,21S,23S,24R,25S,27R)-1,14-dihydroxy-12-[(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl]-23,25-dimethoxy-13,19,21,27-tetramethyl-17-(prop-2-en-1-yl)-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetrone

CAS NO. :- 104987-11-3

FORMULA :- C44H69NO12

SYNONYMS :- FK-506;prograf;fr900506;L 679934;Protopic;Advagraf;Fujimycin;TacroBell;TACROLIMUS;FK-506, 99+%

APPLICATION :- For use after allogenic organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It was first approved by the FDA in 1994 for use in liver transplantation, this has been extended to include kidney, heart, small bowel, pancreas, lung, trachea, skin, cornea, and limb transplants. It has also been used in a topical preparation in the treatment of severe atopic dermatitis.

DESCRIPTION :- Tacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient immune system and so the risk of organ rejection. It is also used in a topical preparation in the treatment of severe atopic dermatitis, severe refractory uveitis after bone marrow transplants, and the skin condition vitiligo. 

Molar mass 804.018 g/mol



Contact Us

Office No. 133, First Floor, DLF City Court, M.G. Road, Near Sikandarpur Metro Station, Gurgaon, Haryana, 122002, India
Phone :+919901284355